Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates

Blood

Volumn 100, Issue 3, 2002, Pages 823-832

  Sandrin, Virginie ^a,b,c   Boson, Bertrand ^a,b,c   Salmon, Patrick ^a,b,c   Gay, Wilfried ^a,b,c   Nègre, Didier ^a,b,c   Le Grand, Roger ^a,b,c   Trono, Didier ^a,b,c   Cosset, François Loïc ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GLYCOPROTEIN; HEMAGGLUTININ; LENTIVIRUS VECTOR; PROTEIN RD114; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ARTICLE; CHIMERA; CONTROLLED STUDY; EBOLA VIRUS; EMBRYO; FOWL PLAGUE VIRUS; GENE TRANSFER; GIBBON LEUKEMIA VIRUS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTEIN DOMAIN; SIMIAN IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 0036682935     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-11-0042     Document Type: Article

References (74)

1. Lentiviral vectors derived from simian immunodeficiency virus (SIV)
2. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
3. Highly efficient and sustained gene transfer in adult neurons with a lentiviral vector
4. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
5. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector
6. Efficient lentiviral transduction of liver requires cell cycling in vivo
7. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer
8. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors
9. Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins
10. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo
11. Development of an avian leukosis-sarcoma virus subgroup A pseudotyped lentiviral vector
12. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells
13. A chimeric GALV derived envelope glycoprotein harboring the cytoptasmic tail of MLV envelope efficiently pseudotypes HIV-1 vectors
14. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1
15. + cells transduced by concentrated oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein
16. Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors
17. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein
18. - primitive cells capable of reconstituting long-term cultures in vitro and in nonobese diabetic-severe combined immunodeficiency mice in vivo
19. High-level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotyped retroviral vectors and an improved clinically applicable protocol
20. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors
21. Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors
22. Study of receptors for vesicular stomatitis virus in vertebrate and invertebrate cells
23. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum
24. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells
25. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors
26. + cells with lentiviral vectors enables the production of large quantities of transgene-expressing immature and mature dendritic cells
27. Early and persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection
28. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide
29. Development of minimal lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) and their use for the gene transfer in human dendritic cells
30. Generation of high-titer pseudotyped retroviral vectors with very broad host range
31. Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses
32. High titer packaging cells producing recombinant retroviruses resistant to human serum
33. Sequence analysis of amphotropic and 10A1 murine leukemia virus: Close relationship to mink cell focus forming viruses
34. Type C retrovirus inactivation by human complement is determined by both the viral genome and producer cell
35. Simian immunodeficiency virus resistance of macaques infused with interferon beta-engineered lymphocytes
36. Retroviral display of functional binding domains fused to the amino-terminus of influenza haemagglutinin
37. HIV-1 gag proteins: Diverse functions in the virus life cycle
38. Inhibition of release of lentivirus particles with incorporated human influenza virus haemagglutinin by binding to sialic acid-containing cellular receptors
39. Interdependence of hemagglutinin gtycosytation and neuraminidase as regulators of influenza virus growth: A study by reverse genetics
40. Heparin inhibits retrovirus binding to fibronectin as well as retrovirus gene transfer on fibronectin fragments
41. Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: Evidence of direct viral binding to chymotryptic carboxy-terminal fragments
42. + cells on fibronectin fragment CH-296 is inhibited by high concentrations of vector containing medium
43. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors
44. Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap
45. Analysis of 4070A envelope levels in retroviral preparations and effect on target cell transduction efficiency
46. Cellular proteins in HIV virions
47. Synthesis, assembly, and processing of viral proteins
48. Retroviral pseudotypes produced by rescue of Moloney murine leukemia virus vector by C-type, but not D-type, retroviruses
49. Lipid rafts and pseudotyping
50. Direct interaction between the envelope and matrix proteins of HIV-1
51. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail
52. Intracellular interaction of simian immunodeficiency virus Gag and Env proteins
53. Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles
54. Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity
55. pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: Implications for the role of the R peptide and p12E TM in viral entry
56. Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus env protein
57. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells
58. A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody
59. Sensitisation of cells and retroviruses to human serum by alpha(1-3) galactosyltransferase
60. Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation
61. The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent
62. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection
63. Retargeting gene delivery by surface-engineered retroviral vector particles
64. Modifying the host range properties of retrovirat vectors
65. + cells
66. Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction
67. Receptor binding transforms the surface subunit of the mammalian C-type retrovirus envelope protein from an inhibitor to an activator of fusion
68. Inter-relations between sub-domains of the SU that regulate the receptor-mediated transition between the fusion-inhibited and fusion-active conformations of the MLV glycoprotein
69. A unique heparin-binding domain in the envelope protein of the neuropathogenic PVC-211 murine leukemia virus may contribute to its brain capillary endothelial cell tropism
70. The furin protease cleavage recognition sequence of Sindbis virus PE2 can mediate virion attachment to cell surface heparan sulfate
71. RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes
72. Membrane fusion by murine leukemia viruses is activated in cis or in trans by interactions of the receptor-binding domain with a conserved disulfide loop at the carboxy-terminus of the surface glycoproteins
73. Modulation of phosphate uptake and amphotropic murine leukemia virus entry by posttranslational modifications of PIT-2